Back to today’s briefing

Story perspectives

GSK Pursues Ropinirole Approval for Restless Legs Syndrome

2/21/2026

27 5 Full Breakdown

Summary

Story summary

In February 2026, GlaxoSmithKline (GSK) was revealed to be compiling findings on Ropinirole while seeking approval to treat Restless Legs Syndrome (RLS).
In 2005, GSK collaborated with a private hospital in the United States to study Ropinirole's effectiveness for sexual dysfunction.
The summary provides no further details about outcomes or regulatory decisions.

1 of 1

Story summary

In February 2026, GlaxoSmithKline (GSK) was revealed to be compiling findings on Ropinirole while seeking approval to treat Restless Legs Syndrome (RLS).
In 2005, GSK collaborated with a private hospital in the United States to study Ropinirole's effectiveness for sexual dysfunction.
The summary provides no further details about outcomes or regulatory decisions.